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Abstract
Survey nonsampling errors refer to the components of total survey error (TSE) that result from failures in data collection and
processing procedures. Evaluating nonsampling errors can lead to a better understanding of their sources, which in turn, can
inform survey inference and assist in the design of future surveys. Data collected via supplemental questionnaires can provide
a means for evaluating nonsampling errors because it may provide additional information on survey nonrespondents and/or
measurements of the same concept over repeated trials on the same sampling unit. We used a supplemental questionnaire
administered  to  cancer  survivors  to  explore  potential  nonsampling  errors,  focusing  primarily  on  nonresponse  and
measurement/specification errors. We discuss the implications of our findings in the context of the TSE paradigm and identify
areas for future research.
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1. Introduction
A simple survey question such as “Are you currently being treated for cancer?” can be subject to different interpretations. For
persons  who  have  never  been  diagnosed  with  cancer  or  a  malignancy  of  any  kind,  the  response  process  should  be
straightforward. Cancer survivors, defined as a person still living after their initial cancer diagnosis, however, may experience
difficulty in responding regardless of their “true” current treatment status because of the cognitive processes employed. Flaws
in these processes, such as misinterpreting key words or misjudging items or events to include in the response, may contribute
to incorrect responses and result in nonsampling error.
Regardless of steps taken by survey designers to mitigate nonsampling errors, they can still arise when there are weaknesses
in the data collection and processing procedures [1], [2], [3]. Specification, measurement, nonresponse, and processing errors
are all types of nonsampling errors [4]; not controlling or compensating for them can lead to biased inferences.
Survey  error  evaluation  helps  survey  practitioners  understand how best  to  control  and compensate  for  these errors  [4].
Analyzing data collected via supplemental questionnaires or follow-up surveys is one method survey researchers can utilize to
evaluate survey errors [5]. Supplemental questionnaires can provide additional information on survey nonrespondents or can
yield repeated measurements on the same unit for use in nonresponse or measurement error analyses, respectively.
One  opportunity  for  using  a  supplemental  questionnaire  to  assess  nonsampling  errors  arose  when  the  2011  Medical
Expenditure Panel Survey-Household Component (MEPS) fielded a follow-up survey to cancer survivors. Each survey utilized
a different method, later described, to elicit information on whether participants were currently receiving treatment for cancer;
therefore,  we were able to explore potential  measurement/specification errors by comparing these two surveys.  We also
assessed  nonresponse  error  in  the  supplemental  questionnaire  by  analyzing  differences  between  respondents  and
nonrespondents’ data provided in MEPS.
2. Data sources
The Medical Expenditure Panel Survey is the most complete data source on the cost and use of health care and insurance for
the civilian noninstitutionalized US population [6]. It is a multi-purpose survey that can be used by public health researchers to
characterize health care costs for and utilization of health care services by certain health conditions, such as cancer [7]. It has
three main components  – the household,  medical  provider,  and insurance components  – in  this  paper  we focus on the
household component, henceforth referred to as MEPS.
Recognizing the need for a comprehensive data source on health care costs and utilization and other public health issues
relevant  to  cancer  survivors  and  their  families,  in  2011,  the  National  Cancer  Institute  collaborated  with  the  Agency  for
Healthcare Research and Quality, the Centers for Disease Control and Prevention, LIVESTRONG, and the American Cancer
Society to develop a supplemental paper-and-pencil, self-administered questionnaire for cancer survivors identified in MEPS.
This self-administered questionnaire is  formally  referred to as the Experiences with Cancer Survivorship Supplement  [8],
henceforth referred to as the CSAQ. The purpose of the CSAQ was to collect information from cancer survivors on their
experiences  with  cancer,  including  whether  treatment  is  currently  being  sought,  long-lasting  effects  of  the  disease,  and
financial impacts [8]. Together, MEPS and the CSAQ provide the only information system that allows public health researchers
to assess both direct medical costs and opportunity costs for cancer-related events and to characterize associations between
costs and experiences with cancer for a representative sample of cancer survivors from the US civilian noninstitutionalized
population [9].
2.1. MEPS
MEPS is a complex, multi-stage, nationally representative sample of the US civilian noninstitutionalized population. It has been
an annual survey since 1996, supporting national estimates of, including but not limited to, health care use, expenditures, and
disease prevalence. Each year a new sample is drawn as a subsample of households that participated in the prior year’s
National Health Interview Survey, a survey conducted by the National Center for Health Statistics. It  is a household-level
sample meaning that data are collected for all target population members in the household.
MEPS employs an overlapping panel design [10] in which data are collected through a series of five personal visit interviews
via CAPI. During each calendar year data are collected simultaneously for two MEPS panels. One panel is in its first year of
data collection (e.g., in 2011, Rounds 1, 2, and 3 of Panel 16), while the prior year’s panel is in its second year of data
collection (e.g., in 2011, Rounds 3, 4, and 5 of Panel 15). In our analysis, we focused on Round 5 of Panel 15 and Round 3 of
Panel 16 because that is when the CSAQ was administered to eligible MEPS participants.
MEPS is typically completed by one household member who responds for themselves and all other eligible members of the
family.  The respondent is asked to report all health care events and descriptions of those events for themselves and family
members during the reference period. By default, for multi-person families the MEPS respondent serves as a proxy respondent
for everyone else in the family.
Events are reported by type of health care service (e.g., office based physician visit, outpatient hospital visit, and prescription
medicine acquisition) and as part of event reporting, the respondent is asked what condition(s) was (were) associated with the
event. These conditions are then coded into the Clinical Classifications Software (CCS) categories, based on ICD-9-CM codes,
making cancer-related health care service events easily identifiable in MEPS databases. [11].
2.2. CSAQ
The CSAQ was fielded during the Panel 15, Round 5 and Panel 16, Round 3 MEPS interviews and was intended to be
administered upon completion of those two interviews. The CSAQ went through two bouts of cognitive testing to assess
respondents’ answers to and understanding of survey questions [8]. Members, age 18+, of households responding to MEPS
were identified as being eligible to participate in the CSAQ via an affirmative response to the following question in MEPS:
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“(Have/Has) (PERSON) ever been told by a doctor or other health professional that (PERSON) had cancer or a malignancy of
any kind?” These participants were then classified as cancer survivors, using the definition noted above (e.g., a person still
living after their first diagnosis of cancer).
3. Methods
3.1. Identifying those currently being treated for cancer
Identifying CSAQ respondents who were currently being treated for cancer was straight-forward as it was based on an explicit
question in the CSAQ. We classified respondents as currently being treated for cancer via an affirmative response to the
question: “Are you currently being treated for cancer-that is are you planning or recovering from cancer surgery, or receiving
chemotherapy, radiation therapy, or hormonal therapy for your cancer?” All other CSAQ respondents were classified as not
currently being treated.
Since no explicit question exists in MEPS that captures current treatment status for cancer, we created an indicator of this
concept  from other  MEPS data.  We used utilization reports  of  office-based medical  provider  visits,  outpatient  visits,  and
prescription medicines collected in MEPS to create the indicator. These reports contained information that corresponded to the
procedures and treatments explicitly mentioned in the CSAQ current cancer treatment question text (e.g., “surgery, or receiving
chemotherapy, radiation therapy, or hormonal therapy”).
These reports also contain detailed information on the type of MEPS reported events (e.g., a visit to an office-based physician)
for 2011, including date of medical visit/event or purchase/acquisition, types of treatments and services received, specialty of
the  medical  practitioner,  condition  codes  associated  with  the  event/prescription,  expenditures,  sources  of  payment  and
coverage, and for the prescription medicine file, the National Drug Code for the prescribed medicine obtained.
We identified events from the medical provider and outpatient reports that occurred during the reference period of the Panel
15, Round 5 or Panel 16, Round 3 interviews for which the household member identified the event as being associated with
cancer (using the CCS codes) and either saw a medical practitioner with any of the following specialties – oncology, radiology,
or surgery – or received chemotherapy or radiation therapy at the visit. These events were flagged as current cancer treatment
events.
Next,  we identified individuals with prescription medicine reports who acquired a prescription medicine associated with a
cancer condition (using the CCS codes) or were treated with a prescription medicine typically used to treat cancer during the
appropriate reference period. Cancer prescription drugs were identified by the set of National Drug Codes contained in the
National Cancer Institute’s drug tables [12].
We then created a person-level dichotomous indicator for current cancer treatment status from MEPS based on the individual
having at least one event meeting any of the above criteria.
3.2. Analysis
Using only information collected in MEPS, we compared the socio-demographic characteristics and mean annual health care
expenditures of MEPS participants, age 18+, who were eligible to participate in and completed the CSAQ (n = 1,419) to (1) the
2011 MEPS participant sample, age 18+ (n = 24,236); (2) all CSAQ-eligible persons (n = 1,764); and, (3) all CSAQ-eligible, but
nonrespondents to the CSAQ (n = 345).
For MEPS participants who were eligible to participate in the CSAQ, we compared MEPS reports of cancer-related conditions
among CSAQ respondents and nonrespondents. We note that comparing CSAQ respondents to CSAQ nonrespondents may
provide insight into the potential nonresponse errors in the CSAQ.
Finally, for CSAQ participants, we assessed the agreement between their responses to the explicit current cancer treatment
status question in the CSAQ to the corresponding MEPS indicator. Agreement was assessed using the Kappa statistic, a
statistic  that  corrects  the  percentage  of  agreement  between  raters,  by  taking  into  account  the  proportion  of  agreement
expected by chance  [13]. Because this statistic accounts for chance agreement, we believe this is a more robust measure
agreement than simply percent agreement. We note that comparing the agreement between the two current treatment status
measures provides insight into potential measurement errors.
We also evaluated domain-specific rates of agreement in which domains were defined by each of respondent proxy status of
MEPS, completion timeliness of the CSAQ, cancer type reported in MEPS. We considered self/proxy-respondent status as a
domain because we hypothesized that there should be higher agreement between the two data sources when the CSAQ and
MEPS respondents were identical. The rationale for including completion timeliness of the CSAQ was two-fold. First, CSAQ
respondents who responded for themselves in MEPS may have been primed by event reporting, thus they may have been
thinking about the cancer-related health care events when responding to the CSAQ. Second, the lag time between completing
the  CSAQ  after  MEPS  may  affect  the  cognitive  processes  involved  in  survey  response.  If  the  CSAQ  was  completed
immediately after the MEPS, then any ambiguity regarding what was implied by the word “currently” (in the CSAQ question
text) may have been mitigated for those persons. Finally, since skin cancer is the most common type of cancer diagnosed in
the US, with non-melanoma skin cancers being the most common type, and a large number seek treatment [14], we also
wanted to investigate whether there were differential rates in agreement in current treatment status between non-melanoma
skin and other cancers.
All analyses were weighted to account for the complex sample design and to adjust for nonresponse to the MEPS [10], [15]. All
statistical analyses were performed using either SAS survey procedures (Version 9.3 SAS Institute Inc., Cary, N.C.) or R
(Version i386 3.0.1,  The Comprehensive R Archive Network).  R was used to calculate the standard error  for  the Kappa
statistics  following the method outlined in  Lin  et  al.  [16].  Variances for  estimated means,  proportions,  and Kappas were
estimated,  using  Taylor  series  linearization  [17].  t-tests  were  used  to  assess  whether  there  were  significant  differences
between the CSAQ respondents and nonrespondents on continuous variables and between domain-level Kappa statistics
while Rao-Scott design-adjusted Pearson χ2 tests were used for categorical variables.
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4. Results
4.1. Indications of nonresponse error
Table 1 displays the socio-demographic characteristics of the four groups. We note that estimates from MEPS 18+ participants
and CSAQ-eligibles are presented solely for reference and completeness as no statistical tests were conducted to compare
these groups.
CSAQ respondents and nonrespondents differ significantly with respect to age, race/ethnicity, health insurance status, and
perceived health status (Table 1). CSAQ nonrespondents tended to be younger (15.4% vs. 7.9% in the 18-44 age category, p <
0.01), more likely to be Hispanic (8.4% vs. 4.4%, p < 0.01), less likely to be covered by any source of private insurance (58.4%
vs. 70.6%, p < 0.01), and had lower perceptions of their health status (28.7% vs. 21.6% in the fair/poor category, p < 0.05) than
CSAQ respondents. Though not presented, we did observe that CSAQ nonrespondents had lower mean annual outpatient
health care expenditures than CSAQ respondents ($843 vs. $1,319, p < 0.05), but there were no other statistically significant
differences in expenditures, even by treatment status.
We summarize the distributions for cancer type, years from first cancer diagnosis, years from last treatment, and time of CSAQ
completion separately for CSAQ respondents and nonrespondents (Table 2).
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The percentage distribution of the three main types of cancer – breast,  prostate, and colorectal  – did not differ between
respondents and nonrespondents; however, there was a higher percentage of nonrespondents having a MEPS report of some
other type of cancer (58.6% vs. 52.1%, p < 0.05). There was a higher percentage of respondents who had received their first
cancer diagnosis more than five years ago compared to nonrespondents (65.6% vs. 54.2%, p < 0.01). There was a greater
proportion of item nonresponse for years since first cancer diagnosis among CSAQ nonrespondents (9.9% vs. 2.1%, p < 0.05).
There was a higher percentage of MEPS proxy respondents among CSAQ nonrespondents when compared to respondents
(47.6% vs. 29.5%, p < 0.05). Finally, we note that there was not a statistically significant difference in current treatment status,
based on the MEPS constructed indicator, between CSAQ respondents and nonrespondents.
4.2. Indications of measurement error
In Table 3 we summarize the overall concordance between CSAQ respondents’ responses to the explicit current treatment
status question and the corresponding indicator constructed from MEPS. We observe that 196 CSAQ respondents (or 14.2%)
answered affirmatively to the CSAQ question.
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Of the 1,419 CSAQ respondents, 280 (or 19.9%) of them had evidence of being treated for cancer based MEPS data. The
overall concordance between the MEPS and CSAQ was 82.0%. This is largely due to the high percentage of no evidence of
treatment from either survey (74.0% of CSAQ respondents had no evidence of treatment from both surveys). The Kappa
statistic was 0.37 which represents fair agreement [18].
Concordance between MEPS and the CSAQ for the domains defined by each of whether the CSAQ respondent was also the
MEPS respondent, time of completion of the CSAQ and, type of cancer is presented in Tables 4-6.
Across each level of each domains, the concordance between the measures of current cancer treatment status was at least
80%. As with the overall concordance, this is likely driven by the high percentage of no evidence of treatment from either data
source. In addition, we do not observe any statistically significant differences in the rates of agreement for any domain, but all
level-specific Kappa statistics for each domain represented fair to moderate agreement [18].
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5. Discussion and conclusions
We presented an analysis of a supplemental questionnaire administered to cancer survivors to explore potential measurement
and nonresponse errors. Overall, we found a fair level of agreement between the two sources for current treatment status, but
no  statistically  significant  differences  among any  of  the  domains  considered.  There  were,  however,  differences  between
respondents and nonrespondents.
A priori, we did not make any judgments about whether MEPS or the CSAQ would provide the better method for measuring
current treatment status. Simple questions, with few probes or examples, might be easy and less burdensome to answer [19];
however, they may not align well with the underlying construct (i.e., there may be a specification error). Alternatively, questions
requiring complicated response tasks, e.g., enumerating events that occurred during some time period, might be difficult and
burdensome to answer [20], [21], but these question might align well with the desired construct. As such, survey practitioners
must balance parsimony with burden to mitigate measurement and specification errors.
Since we found more evidence of currently receiving treatment among CSAQ respondents using the MEPS indicator (19.9% in
MEPS  vs.  14.2%  in  the  CSAQ),  then  perhaps  constructing  this  concept  from  a  survey  whose  response  tasks  involve
enumerating specific treatment events is preferred. Specifically, if we operate under the “more is better” premise [22], as is
often the case in surveys that require event and expenditure reporting, then MEPS might be “fit enough” for identifying cancer
survivors currently receiving treatment and less susceptible to specification and measurement errors; acknowledging that, the
CSAQ is still  necessary for assessing other concepts like the relationship among health care costs and experiences with
cancer since the latter are not collected in MEPS.
We note that since we constructed current treatment status from only three types of MEPS utilization reports and did not
incorporate other types of health care service reports, we may have induced a specification error in the constructed indicator.
For example, a breast cancer survivor responding to MEPS might have received a mastectomy but, the details of this surgical
procedure, if part of a hospital stay, would have been included in an inpatient hospital stay report. At first glance, it may seem
that our method would not classify this cancer survivor as currently receiving treatment for cancer, but it is likely that prior to
receiving the mastectomy, the cancer survivor also consulted an oncologist or surgeon in an office-based physician setting.
The physician visit would likely have been identified in our method of identifying individuals currently receiving treatment. Thus,
provided that both events were reported and occurred in the reference period, the MEPS participant would have been correctly
classified in the MEPS indicator.
In light of this example, one area of future research might include broadening the criteria used to classify a MEPS participant
as currently receiving treatment. It would, however, also increase the discordance between the two data sources (because the
set of CSAQ respondents identified as receiving treatment is fixed). Researchers may consider conducting sensitivity analyses
with varying inclusion criteria.
As noted, the MEPS indicator was based on respondent reports of health care service events. There are at least two additional
sources of nonsampling errors in MEPS that could affect the identification of those currently receiving treatment for cancer.
These are underreporting and coding error. Failing to report events can be due memory problems like retrieval failures and
encoding differences [3]  and survey fatigue or  burden [20].  Survey burden can also lead to  satisficing behaviors  and is
particularly relevant to this research [20]. By the time cancer survivors are identified in MEPS and asked to participate in the
CSAQ, they have already potentially participated in the National Health Interview Survey, at least two round of MEPS, and
other MEPS supplemental questionnaires. As a consequence, these respondents have had several opportunities to learn poor
responding behaviors, e.g., learning to say “no” so they are not asked a subsequent battery of questions [23], which could lead
to  underreports  of  cancer-related  events  within  in  an  interview.  Furthermore,  event  characteristics,  such  as  the  medical
condition  associated  with  the  report,  are  provided  in  the  form of  open-ended responses.  Errors  arising  from systematic
differences in conditions being coded will result in biased estimates of those currently receiving treatment from the MEPS
indicator.
Even though a nonresponse adjustment was made to account for MEPS nonresponse, we still observed statistically significant
differences between CSAQ respondents and nonrespondents with respect  to some characteristics.  We did not,  however,
observe a statistically significant difference in the MEPS indicator of current treatment status, suggesting little, if any, evidence
of nonresponse bias in this estimate. However, as Groves [24] cautions, estimates within a survey are likely to vary in terms of
their  nonresponse  bias  properties.  If  there  is  a  correlation  between  some  other  substantive  variable  of  interest  and
nonresponse propensity,  then nonresponse biases may exist  [25].  For example, we observed that there were statistically
significant differences in the percentage of respondents and nonrespondents who had their first cancer diagnosis more than
five years ago (65.6% and 54.2% of respondents and nonrespondents, respectively). It seems plausible that this characteristic
may be correlated with treatment status; thus, inferences about this substantive area might be subject to nonresponse bias.
We note that our analyses were hampered by small sample sizes. This prohibited us from conducting multivariate analyses
with sufficient power to investigate whether there were interactions among any of the domains considered. For example, we
were not able to explore whether there were interactions between proxy/self-response and CSAQ completion timeliness. For
self-respondents to MEPS, it is possible that MEPS could provide retrieval cues to help facilitate the recall  of information
relevant to data collected in the CSAQ. With larger sample sizes via pooling data from possible future administrations of the
CSAQ, these multivariate analyses could potentially be conducted.
One final  area of  research is  to  explore the potential  sources of  coverage error  associated with  the screening methods
employed in MEPS to determine eligibility for the CSAQ. To investigate potential coverage errors, using the MEPS indicator,
we examined the subset of MEPS sample members that were identified as currently receiving treatment, but were ineligible to
participate in the CSAQ. 460 MEPS participants were identified as currently receiving treatment based, but only 330 of them
were eligible for participation in the CSAQ. The majority of these discrepant cases (106 out of 130) had their first cancer
diagnosis prior to age 18, so they were, in fact, ineligible to participate in the CSAQ. Of the remaining 24, nine became
out-of-scope during that round of data collection (e.g., died or institutionalized), but there were an additional 15 that were still
ineligible for CSAQ participation. When administered the CSAQ, these 15 reported that their cancer diagnosis report from
MEPS was an error. Ten of these 15 respondents were also the MEPS respondent while five had MEPS proxy respondents.
Additional research pertaining to coverage error could explore these types of erroneous reports, i.e., were they the result of
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satisficing behaviors or misinterpreting the survey questions?
Finally it is important to acknowledge that survey practitioners can learn a great deal from supplemental questionnaires or
follow-up surveys. These types of data sources offer unique opportunities for assessing survey errors since analyses can be
conducted within the same unit and often provide additional information about the sample unit. Understanding these errors can
lead to enhancements for and improvements of future surveys. Furthermore, supplemental questionnaires that piggy-back onto
existing surveys are useful for targeting areas of research and researchers should not feel limited to using only one source. To
the extent possible, they should consider combining the data sources to maximize the information available for analysis.
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